序号 |
标题 |
次数 |
作者 |
发布时间 |
74746 |
MWCNT/PEI-FI-DOTA(Gd)-PEG 异硫氰酸荧光素(FI)和钆(Gd)螯合剂共价接枝聚乙烯亚胺修饰的多壁碳纳米管 |
120 |
h |
2024-12-19 |
74747 |
DOTA-Cys-hAb47 螯合剂DOTA偶联半胱氨酸-抗EphB4抗体hAb47和hAb131 |
154 |
h |
2024-12-19 |
74748 |
1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-F(ab)2-曲妥珠单抗 |
80 |
h |
2024-12-19 |
74749 |
DOTA-MG11(DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp)DOTA肽缀合物 |
105 |
h |
2024-12-19 |
74750 |
AcLys-PABC-VC-Aur0101, cas:1438851-17-2,ADC定制 |
134 |
wyh |
2024-12-19 |
74751 |
cas:107348-47-0,2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate ADC抗体偶联药物 |
71 |
zyl |
2024-12-19 |
74752 |
SMCC-DM4 , cas:1228105-52-9,ADC定制 |
74 |
wyh |
2024-12-19 |
74753 |
cas:1639939-40-4 Mal-Val-Ala-PAB-PNP |
75 |
zyl |
2024-12-19 |
74754 |
MA-PEG8-VA-PAB-SG3199,ADC定制 |
91 |
wyh |
2024-12-19 |
74755 |
Acid-PEG4-Val-Cit-PAB-MMAE |
67 |
zyl |
2024-12-19 |
74756 |
MC-Val-Cit-PAB-Indibulin,cas:2055896-95-0,ADC定制 |
82 |
wyh |
2024-12-19 |
74757 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
80 |
zyl |
2024-12-19 |
74758 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
80 |
zyl |
2024-12-19 |
74759 |
MC-Sq-Cit-PAB-Dolastatin10 ,cas:1941168-65-5,ADC定制 |
95 |
wyh |
2024-12-19 |
74760 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
86 |
zyl |
2024-12-19 |
74761 |
N3-PEG4-DYKDDDD-Doxorubicin,ADC定制 |
103 |
wyh |
2024-12-19 |
74762 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
66 |
zyl |
2024-12-19 |
74763 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
88 |
zyl |
2024-12-19 |
74764 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
83 |
zyl |
2024-12-19 |
74765 |
MC-GGFG-DX8951 cas:1600418-29-8 |
75 |
zyl |
2024-12-19 |
74766 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
91 |
h |
2024-12-19 |
74767 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
185 |
zyl |
2024-12-19 |
74768 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
89 |
h |
2024-12-19 |
74769 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
117 |
h |
2024-12-19 |
74770 |
VC-SECO DUBA analogue,ADC定制 |
92 |
wyh |
2024-12-19 |
74771 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
89 |
h |
2024-12-19 |
74772 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
112 |
h |
2024-12-19 |
74773 |
Vc-MMAD cas:1401963-17-4的结构式 |
72 |
zyl |
2024-12-19 |
74774 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
98 |
h |
2024-12-19 |
74775 |
CL2A-SN38,cas:1279680-68-0,ADC定制 |
169 |
wyh |
2024-12-19 |
74776 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
74 |
h |
2024-12-19 |
74777 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
150 |
h |
2024-12-19 |
74778 |
MC-MMAF , cas:863971-19-1,ADC定制 |
111 |
wyh |
2024-12-19 |
74779 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
135 |
zyl |
2024-12-19 |
74780 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
86 |
h |
2024-12-19 |
74781 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
97 |
h |
2024-12-19 |
74782 |
Vc-MMAE, cas:646502-53-6,ADC定制 |
129 |
wyh |
2024-12-19 |
74783 |
Azido-PEG4-MMAE |
114 |
zyl |
2024-12-19 |
74784 |
cas:2055024-59-2,Fmoc-PEG2-Val-Cit-PAB-OH |
113 |
zyl |
2024-12-19 |
74785 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin,ADC定制 |
116 |
wyh |
2024-12-19 |
74786 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
70 |
h |
2024-12-19 |
74787 |
cas:1807530-16-0,2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
87 |
zyl |
2024-12-19 |
74788 |
DOTA偶联受体特异性肽 |
116 |
h |
2024-12-19 |
74789 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
96 |
h |
2024-12-19 |
74790 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
98 |
h |
2024-12-19 |